Tuesday, 20 Nov 2018

You are here

Cardiovascular Benefits of Maintaining Biologic Therapy

An Australian prospective study of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has shown that sustained use of tumour necrosis factor (TNFi) inhibitors or biologics can reduce the risks of cardiovascular events (CVEs).

Studies have shown that the risk of major cardiovascular events (MACE) is elevated and not significantly different between RA and AxSpa or PsA (http://bit.ly/2MoHFNs).

A total of 4140 consecutive patients from the Australian Rheumatology Association Database with RA, PsA and AS, were followed between September 2001 to January 2015 and were included in the study.

An analysis of 19,627 patient-years showed that (after multivariate adjustment) the CVE risk was lower with TNFI (HR 0.85, 95% CI 0.76–0.95) and other biologic therapies (HR 0.81, 95% CI 0.70–0.95), but not in those who had stopped their biologic agents (HR 0.96, 95% CI 0.83–1.11). CVE risk was the same between RA, PsA and AS patients. 

These studies are similar to other showing the protective CV benefits of sustained therapy with either methotrexate or TNFi. 

This is important as a recent claims database study of 10,254 patients with RA, PsA, or Psoriasis seen between 2006-2015 showed that after initial CV event 15.3% discontinued and 15.5% switched DMARD therapy after index CV event. Independent predictors of DMARD discontinuation included PsO diagnosis, renal disease, hypertension, heart failure, diabetes mellitus, older age, and baseline csDMARD or non-TNFi bDMARD use (vs TNFi bDMARDs).  (http://bit.ly/2nzKeOs)

In their study, having RA and heart failure at baseline, but not DMARD use after index event, were independently associated with increased risk of a subsequent CV event.


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Growing Tick Population Comes with Health Concerns

CNN has published a recent government report from the Tick-Borne Disease Working Group that suggests the US tick population is growing and may bring with it an increase in tick-related illnesses. 

While Lyme disease is the most popular of tick-borne illnesses, there are another 20 known conditions related to tick bites.

Chikungunya Virus Vaccine Developed

Lancet reports on a new vaccine for Chikungunya fever (MV-CHIK) demonstraing excellent safety, tolerability and good immunogenicity, independent of pre-existing immunity against the vector. MV-CHIK is a promising vaccine for the prevention of chikungunya fever.

Subclinical Heart Inflammation Seen in RA

Subclinical myocardial inflammation is common among patients with rheumatoid arthritis (RA) and is associated with articular disease activity, researchers reported.

A New Era? JAK inhibitors in the Management of RA

ACR 2018 has come and gone. It was a conference filled with a number of highlights. One thing from this conference which really stood out was the continued plethora of data on JAK inhibitors. First in RA, and now in psoriatic arthritis and psoriasis.

Spotlight on Interstitial Lung Disease at ACR 2018

Here are a few important advances in our understanding of interstitial lung disease (ILD) from the ACR 2018 meeting last week.